Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome
- Chunhua Jin,
- Yejoo Jeon,
- Daniel T. Kleven,
- Jennifer S. Pollock,
- John J. White,
- David M. Pollock(corresponding author)
- University of Alabama at Birmingham,
- Medical College of Georgia,
- ,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>Experiments determined whether the combination of endothelin A (ET<sub>A</sub>) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone. Male Dahl saltsensitive rats were fed a high-fat (36% fat), high-salt (4% NaCl) diet for 4 weeks. Separate groups of rats were then treated with vehicle (control), ABT-627 (ABT; 5 mg/kg per day, in drinking water), chlorthalidone (CLTD; 5 mg/kg per day, in drinking water), or both ABT plus CLTD. Mean arterial pressure (MAP) was recorded continuously by telemetry. After 4 weeks, both ABT and CLTD severely attenuated the development of hypertension, whereas the combination further reduced MAP compared with ABT alone. All treatments prevented proteinuria. CLTD and ABT plus CLTD significantly reduced nephrin (a podocyte injury marker) and kidney injury molecule-1 (a tubulointerstitial injury marker) excretion. ABT, with or without CLTD, significantly reduced plasma 8-oxo-2'-deoxyguanosine, a measure of DNA oxidation, whereas CLTD alone had no effect. All treatments suppressed the number of ED1<sup>+</sup> cells (macrophages) in the kidney. Plasma tumor necrosis factor receptors 1 and 2 were reduced only in the combined ABT and CLTD group. These results suggest that ABT and CLTD have antihypertensive and renal-protective effects in a model of metabolic syndrome that are maximally effective when both drugs are administered together. The findings support the hypothesis that combined ET<sub>A</sub>antagonist and diuretic treatment may provide therapeutic benefit for individuals with metabolic syndrome consuming a Western diet.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 467-473 (7 pages)Journal (Volume, Issue Number)
Journal of Pharmacology and Experimental Therapeutics (Volume 351, Issue 2)Publication milestones
- Published - 11/01/2014
Publication status
Published - 11/01/2014
ISSN
0022-3565Publication IDs
- Scopus: 84908125790
- PubMed: 25189702
Publication metrics
Metrics
SciVal
FWCI
0.22
SciVal
Author count
6
SciVal
citations
8
SciVal
Paper percentile
63
Fractional count
2
Fractional count
0.33
Fractional count
4
Fractional count
0.67
Fractional count
2
Fractional count
1
PlumX, opens in new tab
Citation count
11
Captures
21
Funding Details
FundersFunding numbers
NHLBI
P01HL095499, P01HL069999
NIDDK
P30DK079626
